Reports Q2 revenue $2.76B, consensus $2.73B. “Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15.2% which includes 5.2% from organic revenues, as well as adjusted EPS growth of 11.5%,” said Jim Davis, chairman, CEO and president.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Notable companies reporting before tomorrow’s open
- Quest Diagnostics price target lowered to $175 from $176 at UBS
- Quest Diagnostics introduces testing for Oropouche virus
- Quest Diagnostics: Strategic Positioning and Growth Potential Amid Reimbursement Challenges
- Quest Diagnostics to develop multi-cancer blood test with MD Anderson Center